Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Public ClinicalTrials.gov record NCT06526793. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Modular Phase 2, Single-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Surovatamig (AZD0486) in Participants With Relapsed or Refractory (R/R) B-cell Non-Hodgkin Lymphoma (SOUNDTRACK-B)
Study identification
- NCT ID
- NCT06526793
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 240 participants
Conditions and interventions
Interventions
- Surovatamig Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 26, 2024
- Primary completion
- Mar 9, 2027
- Completion
- Jun 13, 2029
- Last update posted
- Feb 24, 2026
2024 – 2029
United States locations
- U.S. sites
- 22
- U.S. states
- 17
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Phoenix | Arizona | 85054 | Not yet recruiting |
| Research Site | Duarte | California | 91010 | Recruiting |
| Research Site | Jacksonville | Florida | 32224 | Not yet recruiting |
| Research Site | Tampa | Florida | 33612 | Recruiting |
| Research Site | Chicago | Illinois | 60637 | Not yet recruiting |
| Research Site | Iowa City | Iowa | 52242 | Not yet recruiting |
| Research Site | Waukee | Iowa | 50263 | Recruiting |
| Research Site | Overland Park | Kansas | 66204 | Withdrawn |
| Research Site | Rochester | Minnesota | 55905 | Recruiting |
| Research Site | St Louis | Missouri | 63110 | Withdrawn |
| Research Site | New Brunswick | New Jersey | 08901 | Withdrawn |
| Research Site | New York | New York | 10016 | Recruiting |
| Research Site | Charlotte | North Carolina | 28204 | Recruiting |
| Research Site | Columbus | Ohio | 43210 | Recruiting |
| Research Site | Portland | Oregon | 97239 | Recruiting |
| Research Site | Philadelphia | Pennsylvania | 19104 | Recruiting |
| Research Site | Pittsburgh | Pennsylvania | 15232 | Withdrawn |
| Research Site | Nashville | Tennessee | 37203 | Not yet recruiting |
| Research Site | Austin | Texas | 78704 | Not yet recruiting |
| Research Site | Houston | Texas | 77030 | Recruiting |
| Research Site | San Antonio | Texas | 78229 | Not yet recruiting |
| Research Site | Milwaukee | Wisconsin | 53226 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 71 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06526793, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 24, 2026 · Synced Apr 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06526793 live on ClinicalTrials.gov.